Abstract 145P
Background
The emergence of immune checkpoint inhibitors (ICIs) in recent years has revolutionised the therapeutic landscape in non-small cell lung cancer (NSCLC), but the overall response rate (ORR) is low, although TMB and MSI show some predictive value for immune efficacy. In real-world clinical practice, however, immunotherapy decisions for many patients must be made on the basis of limited clinical information. Here, we developed a machine learning-based clinical decision support algorithm to synthesise multidimensional clinical information to predict therapeutic response to ICI in NSCLC patients and reduce the rate of first-line therapeutic misdosing.
Methods
A total of 66 clinical characteristics and biochemical indexes were collected from electronic medical records, and correlated with optimal clinical efficacy. Neural network algorithm, was used to predict immune response and then validated in an independent validation set of ICI-treated patients.
Results
A total of 402 patients were enrolled in the study, including 321 patients in the training set (ORR, 57.3%) and 81 patients in the test set (ORR, 58%). Neural network algorithm showed a superior pronounced predictive effect (area under the curve [AUC] 0.71) using only eight common clinical parameters, which included sex, age, tumor subtype, smoking history, lymphocyte, eosinophil, neutrophil, and erythrocyte distribution width. The overall accuracy in the validation set was 70.4%, the positive predictive value (PPV) was 70.2% and the negative predictive value (NPV) was 70.8%. The model was able to identify 50% of these poorly treated patients (17/34), mainly non-responders and hyper-progressors, in a timely manner prior to dosing, resulting in a 50% reduction in the rate of clinical misses.
Conclusions
Overall, our neural network algorithm provides a rapid clinical decision support model for predicting ICI treatment response in NSCLC patients. Furthermore, this model relies only on basic clinical information and biochemical indicators, which can effectively reduce clinical overdosing in the first-line setting.
Clinical trial identification
Editorial acknowledgement
Legal entity responsible for the study
OrigiMed Shanghai Co., Ltd.
Funding
Has not received any funding.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
102P - Dynamic profiling of ctDNA in HER2-alterated advanced NSCLC treated with pyrotinib and apatinib: Exploratory biomarker analysis from a phase II trial
Presenter: Yucheng Dong
Session: Poster session 08
103P - Epigenetic regulated genes enhanced fragmentomics-based model for early-stage lung cancer detection
Presenter: Yadong Wang
Session: Poster session 08
104P - The development of a classifier of somatic copy number alteration burden in liquid biopsy with potential clinical impact in advanced non-small cell lung cancer (NSCLC)
Presenter: Laura Bonanno
Session: Poster session 08
105P - Plasma ctDNA dynamics as clinical response biomarker for NSCLC: A systematic review and meta-analysis
Presenter: Luís Leite
Session: Poster session 08
106P - Longitudinal molecular characterization in plasma of EGFR mutant non-small cell lung cancer (NSCLC) experiencing early progression (EPD) on first-line osimertinib (Osi)
Presenter: Laura Bonanno
Session: Poster session 08
107P - Germline pathogenic variants identified in tissue- and blood-based whole exome sequencing in advanced solid tumors
Presenter: Takeshi Kuwata
Session: Poster session 08
108P - Assessing molecular characteristics in a large cohort of anal squamous cell carcinoma patients
Presenter: Cristina Smolenschi
Session: Poster session 08
109P - Development and validation of a digital PCR assay for detection and monitoring of universally methylated circulating tumor DNA in patients with high-grade sarcoma
Presenter: Elisabeth Ashton
Session: Poster session 08
110P - 13-plex non-invasive genotyping in HPV related cancers in the MOSCATO trial
Presenter: Elise Rupp
Session: Poster session 08
111P - Leveraging circulating tumor DNA sequencing for first-line cancer treatment: Insights from two prospective precision medicine studies
Presenter: Veronique Debien
Session: Poster session 08